About Rivas Capital
Rivas Capital is a venture capital firm founded in 2011. It is primarily based out of Cambridge, United States. As of Jan 2024, Rivas Capital has invested in 20 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and High Tech. Most recently it participated in the $***** Series F round of Inari Overall, Rivas Capital portfolio has seen 3 unicorns, 3 IPOs and 1 acquisition including key companies like Zipline, Clarify and Kodiak Sciences. A lot of funds co-invest with Rivas Capital, with names like Insight Partners sharing a substantial percentage of its portfolio. Rivas Capital has team of 2 people including 1 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series C & 3 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Rivas Capital's List of Top Investments
Rivas Capital has a portfolio of 20 companies, including 3 unicorns. Their most notable investments are in Aircuity and ReviveMed.Their portfolio spans across and United States. They have invested in Life Sciences, Enterprise Applications, High Tech and 9 other sectors, across stages such as Series A, Series C and 3 more. Here is the list of top investments by Rivas Capital:1. Zipline
Operator of drone delivery and logistics. It supports local communities on a global scale.
Key facts about Zipline
- Founded Year: 2011
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series H
- Total Funding till date: $1.63B
- Employee Count: 23 as on Sep 30, 2026
- Investors: K2 Global, StraightPath Venture Partners and 66 Others
- Latest Funding Round: Series H, Aug 17, 2026, $*****
- Highlight: Editors' Pick
2. Clarify
Clarify Health is a healthcare analytics and value-based payments platform company that empowers payers, providers, and life sciences companies to deliver better care, therapies, and outcomes with actionable patient journey insights. Clarify’s products illuminate actionable opportunities to drive growth, optimize networks, improve care delivery, manage population health, maximize value-based care performance, and bring therapies to market. With Clarify, healthcare organizations can leapfrog from point-solution and manual analytics to self-service, rapid generation of enterprise insights that light the path to better care and outcomes.
Key facts about Clarify
- Founded Year: 2015
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $411M
- Employee Count: 126 as on Aug 31, 2026
- Investors: Spark Capital, SoftBank Vision Fund and 22 Others
- Latest Funding Round: Series D, Apr 05, 2022, $*****
- Highlight: Editors' Pick
Developer of therapeutics to treat retinal diseases. The company has two drugs in the developmental stage includes KSI 301 for Age-related macular degeneration (AMD) and KSI 501 for Dry AMD. KSIs are built on proprietary science antibody bioconjugate product platforms.
Key facts about Kodiak Sciences
- Founded Year: 2009
- Location: Palo Alto (United States)
- Stage: Public
- Total Funding till date: $35.8M
- Employee Count: 135 as on Sep 30, 2026
- Investors: ArrowMark Partners, Perceptive Advisors and 1 Other
- Latest Funding Round: Conventional Debt, Apr 26, 2018, $*****
- Highlight: Public
4. Inari
Developer of technology to improve crop breeding and seed production. The company utilizes innovations in genomics, artificial intelligence, and gene editing to analyze plant DNA. It aims to identify edits that will positively impact specific locations within a crop's DNA. The company focuses on enabling plants to make efficient use of resources.
Key facts about Inari
Developer of fluorescence-guided imaging technologies to help surgeons detect residual cancer tissue during operations. The company’s product is the Lumicell Direct Visualization System, designed to provide real-time illumination of cancerous tissue within the breast cavity during the initial lumpectomy, potentially reducing repeat surgeries. Lumicell’s proprietary, pan-oncologic optical imaging agent is also being explored across a wide variety of solid tumor indications.
Key facts about Lumicell Diagnostics
- Founded Year: 2008
- Location: Wellesley (United States)
- Valuation: $*****
- Stage: Series D
- Total Funding till date: $361M
- Employee Count: 62 as on Aug 31, 2026
- Investors: Kodiak Venture Partners, Rivas Capital and 8 Others
- Latest Funding Round: Series D, Apr 22, 2025, $*****
- Highlight: Editors' Pick
Rivas Capital's Year-on-Year Investment Trends
Rivas Capital has invested in 20 companies over the last 11 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in GreenLight Biosciences and most recent follow-on round was in Inari.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 1 | 1 |
2023 | 0 | 0 | 0 |
2022 | 2 | 1 | 3 |
2021 | 2 | 0 | 2 |
2020 | 0 | 0 | 0 |
2019 | 0 | 0 | 0 |
2018 | 1 | 1 | 2 |
Rivas Capital's Investments by Stage
Rivas Capital has made 2 investments in Series A stage with an average round size of $25.6M, 2 investments in Series C stage with an average round size of $60.6M, 1 investment in Post IPO stage with an average round size of $109M, 1 investment in Seed stage with an average round size of $1.5M and 1 investment in Series D stage with an average round size of $208M.Stage of entry | No. of Investments |
|---|---|
Series A | 2 |
Series C | 2 |
Post IPO | 1 |
Seed | 1 |
Series D | 1 |
Note: We have considered here, only first round of investments
Rivas Capital's Investments by Sector
Rivas Capital has a diverse portfolio, with companies operating in the Enterprise Applications, High Tech, Life Sciences, Energy Tech and Environment Tech. Notably, it has invested in 17 Tech companies, 16 Enterprise (B2B) companies, 9 Software companies and at least 4 companies focusing on Tech hardware.Sector | No. of Investments |
|---|---|
Enterprise Applications | 6 |
High Tech | 3 |
Life Sciences | 3 |
Energy Tech | 1 |
Environment Tech | 1 |
Others | 7 |
Note: We have considered here, only first round of investments
Rivas Capital's Investments by Geography
Rivas Capital has made most investments in United States (7).Rivas Capital's recent investments
Rivas Capital has not made any investment in 2026 so far.Here are the most recent investments by Rivas Capital:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jan 30, 2024 | United States | Series F | 8439 | [+5] | |
Aug 12, 2022 | United States | Post IPO | 2333 | ||
Apr 05, 2022 | United States | Series D | 5362 | [+7] | |
Mar 01, 2022 | United States | Series A | 8158 | [+5] | |
May 10, 2021 | United States | Series D | 6900 | [+5] |
Unicorns in Rivas Capital's Portfolio
Rivas Capital has 3 unicorns in its portfolio - Clarify, Inari and Zipline. The most recent unicorn in their portfolio is Clarify. It became a unicorn in 2022, 1 years after Rivas Capital first invested in it.Here is a list of unicorns in Rivas Capital's portfolio:
Tracxn Score | Company | Short Description | Founded year | Sector | Location | Company Stage | First Investment/ Acquisition Details |
|---|---|---|---|---|---|---|---|
65 | Company provides healthcare analytics and value-based payments platform services | 2015 | San Francisco | Series D | gpctzxt | ||
63 | Developer of technology to improve crop breeding and seed production | 2016 | Cambridge | Series G | yx{inwi | ||
65 | Operator of drone delivery and logistics | 2011 | San Francisco | Series H | hfwmqv{ |
IPOs and Publicly Listed companies in Rivas Capital's Portfolio
3 of Rivas Capital's portfolio companies have become public. GreenLight Biosciences got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Feb 2022 at marketcap of $44.9M and Frequency Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $426M.Here are Rivas Capital's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Feb 03, 2022 | Aug 12, 2022 | Post IPO | 9133 | |
Oct 03, 2019 | - | - | 1707 | |
Oct 04, 2018 | - | - | 7385 |
Acquired companies in Rivas Capital's Portfolio
1 company from Rivas Capital's portfolio has been acquired. The most recent acquisition was Glympse Bio in Aug 2023 by Sunbird Bio for $*****.Here are Rivas Capital's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Aug 09, 2023 | - | - | 9272 |
Team profile of Rivas Capital
Rivas Capital has a team of 2 members located in United Kingdom. Rivas Capital's team does not sit on the board of any company as of now.Co-investors of Rivas Capital
Over the past 11 years, 85 investors have co-invested in Rivas Capital's portfolio companies. This includes funds and angels.
- Invested before Rivas Capital: KKR, tlg.global and 31 others have invested in rounds before Rivas Capital. There is 1 company where KKR has invested before Rivas Capital and 1 company where tlg.global has invested before Rivas Capital.
- Top Co-investors of Rivas Capital: 34 investors entered a company along with Rivas Capital. These include investors like Insight Partners (1 company).
- Invested after Rivas Capital: A total of 18 investors have invested in Rivas Capital's portfolio after their investments. Top Investors include SoftBank Vision Fund (1 company), BlackRock (1 company) and Memorial Hermann (1 company).
Recent News related to Rivas Capital
•
Inari raises another $103M for gene-editing technologyInside INdiana Business•Feb 06, 2024•Inari, Hanwha Impact, CPP Investments, Rivas Capital and 6 others
•
GreenLight Biosciences announces $109 million financingInvesting News•Aug 12, 2022•GreenLight Biosciences, S2G Ventures, http://bnpparibas-am.be, Continental Grain Company and 8 others
•
Clarify Health’s $150 Million Series D FinancingGlobal Legal Chronicle•Apr 13, 2022•Latham & Watkins, Clarify, SoftBank Vision Fund, BlackRock and 7 others
•
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to PatientsBusiness Wire•Mar 01, 2022•NextRNA, Cobro Ventures, Lightchain Capital, Circle Squared and 4 others
•
AgTech Startup Inari Nabs New Funding at $1.2 Billion ValuationBloombergQuint•May 12, 2021•Inari, Flagship Pioneering, Alexandria, Investcorp and 5 others
•
Clarify Health Scores $115m In Funding For Clinical Analytics PlatformMobiHealthNews•Mar 17, 2021•Clarify, Spark Capital, Concord Health Partners, HWVP and 6 others
•
Intel Capital pumps $72M into AI, IoT, cloud and silicon startups, $115M invested so far in 2018TechCrunch+•May 08, 2018•Intel, Alauda, Intel Capital, Mingzhao Capital and 50 others
•
